Newly named Novo Nordisk Haemophilia & Haemoglobinopathies Foundation reveals its future direction
On 5 December the Novo Nordisk Haemophilia & Haemoglobinopathies Foundation (NNHF), formerly known as the Novo Nordisk Haemophilia Foundation, announced a new chapter in its mission to improve access to care for people living with haemophilia and haemoglobinopathies in low- and middle-income countries.
Since 2005, the NNHF has been supporting people living with haemophilia, a rare bleeding disorder, in low-middle-income countries and building sustainable solutions through partnerships and capacity-building initiatives.
The NNHF is now formally expanding its scope to include sickle cell disease and thalassaemia – both of which are haemoglobinopathies – addressing the needs of over 10 million people worldwide living with these conditions – 80% of whom reside in low- and middle-income countries.
Individuals affected by haemophilia and haemoglobinopathies face severe challenges that impact their health outcomes and quality of life. Learn more about these serious conditions on the NNHF website: Novo Nordisk Haemophilia Foundation (NNHF) – Impacting care. Together.
NNHF’s strategy will:
- Apply its proven, partnership-led model to develop tailored programmes adapted to local needs.
- Empower healthcare professionals and families through education and advocacy.
- Drive sustainability by fostering local ownership and long-term solutions.
Learn more about how the NNHF is « Impacting care. Together » by visiting nnhf.org.
Or watch the Unveiling film now on YouTube.
Tags